| 产品描述: | Molnupiravir (EIDD-2801) 是核糖核苷类似物 EIDD-1931 的口服生物可利用的异丙酯前药。Molnupiravir 显示出广泛的抗流感病毒 (influenza virus) 和coronaviruses的活性,如 SARS-CoV-2,MERS-CoV,SARS-CoV。Molnupiravir 有用于 COVID-19 和季节性,流行性流感的潜力。 |
| 靶点: |
SARS-CoV;InfluenzaVirus |
| 体内研究: |
Molnupiravir (50-500 mg/kg; p.o.; every 12 hours for 3 days) is robustly antiviral and able to prevent SARS-CoV replication and disease[1]. Molnupiravir (7 mg/kg; p.o.; twice daily for 3.5 days) significantly reduces shed virus load and duration of fever. |
| 参考文献: |
1.Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883. 2. Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: eaax5866. |
| 溶解性: |
Souble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.037 ml |
15.183 ml |
30.367 ml |
| 5 mM |
0.607 ml |
3.037 ml |
6.073 ml |
| 10 mM |
0.304 ml |
1.518 ml |
3.037 ml |
| 50 mM |
0.061 ml |
0.304 ml |
0.607 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |